PRTO - Bragar Eagel & Squire P.C. is Investigating the Board of Directors of Proteon Therapeutics Inc. (NASDAQ: PRTO) on Behalf of Proteon Shareholders and Encourages Proteon Investors to Contact the Firm

NEW YORK, Sept. 25, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Proteon Therapeutics, Inc. (NASDAQ: PRTO) on behalf of Proteon shareholders concerning the proposed merger with ArTara Therapeutics, Inc.

Click here to participate in the action.

Pursuant to the proposed transaction announced on September 23, 2019, Proteon shareholders will own 10% of the combined company. The investigation focuses on whether Proteon and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

If you own Proteon shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, or by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information concerning our investigation of Proteon please go to https://bespc.com/prto/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. 

SOURCE Bragar Eagel & Squire, P.C.